Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
This self-injected drug promises to treat Type 2 diabetes and, to some extent, promote weight loss
It references a 30-day supply of the Wegovy pill as one month
Researchers examining multi-pathway interactions or running comparative trials find it flexible enough to use alongside other peptide compounds, provided they are operating within controlled frameworks
Key Highlights Orforglipron (Eli Lilly) * 13.6% weight loss in Phase 2 * 2.1% HbA1c reduction * Highest efficacy among the three molecules in Phase 2 * Subsequently confirmed efficacy in Phase 3 with up to 14.7% weight loss * First and only FDA-approved oral small-molecule GLP-1 receptor agonist (Foundayo) Elecoglipron (AstraZeneca) * 11.8% weight loss * 1.9% HbA1c reduction * Strong Phase 2b results * Currently advancing into a global Phase 3 program Aleniglipron (Structure Therapeutics) * 12.1% weight loss * 1.5% HbA1c reduction * Encouraging efficacy with ongoing Phase 3 development Phase 2 Efficacy Comparison Weight Loss * Orforglipron: 13.6% * Aleniglipron: 12.1% * Elecoglipron: 11.8% HbA1c Reduction * Orforglipron: 2.1% * Elecoglipron: 1.9% * Aleniglipron: 1.5% As Structure Therapeutics expanded their testing into the ACCESS II trial and evaluated higher doses (specifically escalation protocols reaching 180 mg and 240 mg), the efficacy numbers jumped significantly
It mimics two gut hormones and has been shown to be more effective than semaglutide in managing blood sugar control
provides both these high-quality peptides, allowing for informed choices based on individual needs
US$ 24.57
US$ 21.51
US$ 23.06
US$ 23.95
US$ 22.66
US$ 20.51
